Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE vs NEOMYCIN & POLYMYXIN B SULFATES & BACITRACIN ZINC & HYDROCORTISONE
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis. Polymyxin B is a cationic detergent antibiotic that disrupts bacterial cell membrane integrity by interacting with phospholipids. Hydrocortisone is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
Neomycin, polymyxin B, and bacitracin are antibiotics that inhibit bacterial protein synthesis, disrupt cell membrane integrity, and interfere with cell wall synthesis, respectively. Hydrocortisone is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
Otic infections: treatment of superficial bacterial infections of the external auditory canal (acute otitis externa),Otic infections: treatment of infections of mastoidectomy and fenestration cavities,Ophthalmic infections: treatment of corticosteroid-responsive inflammatory ocular conditions with concurrent bacterial infection (off-label)
Treatment of corticosteroid-responsive dermatoses with secondary bacterial infection
Instill 3 to 4 drops into the affected ear(s) 3 to 4 times daily. For otic suspension in adults.
Apply to affected area 3-4 times daily. Not for use in eyes.
Neomycin: 2-3 hours (in adults with normal renal function); may accumulate in renal impairment. Polymyxin B: 6-8 hours (prolonged in renal impairment: up to 36 hours). Hydrocortisone: 1.2-1.5 hours (terminal).
Neomycin: 2-3h (normal renal); polymyxin B: 4-6h (normal renal), prolonged to 2-3 days in renal impairment; bacitracin: ~1.5h after IM; hydrocortisone: 1.5-2h (plasma). Topical: systemic levels negligible.
No systemic absorption expected with otic use; no dose adjustment required.
No adjustment necessary for ophthalmic/otic/topical use due to minimal systemic absorption.
None.
Neomycin and polymyxin B sulfates are poorly absorbed from intact skin, thus systemic exposure is minimal and teratogenic risk is low. Hydrocortisone is a corticosteroid; topical use in pregnancy is generally considered safe at low doses and short duration. However, prolonged use of high-potency corticosteroids may increase risk of orofacial clefts (first trimester) and fetal growth restriction (second/third trimester). The combination product is classified as Pregnancy Category C. Risk cannot be ruled out; use only if clearly needed.
This combination product (neomycin, polymyxin B, hydrocortisone) is an otic suspension used for bacterial otitis externa with inflammation. Neomycin is an aminoglycoside with good activity against Gram-negative rods; polymyxin B covers Gram-negative rods including Pseudomonas; hydrocortisone reduces inflammation. Avoid use in patients with tympanic membrane perforation due to risk of ototoxicity from neomycin. Shake well before use. For optimal contact, patient should lie on side with affected ear up for 5 minutes after instillation.
This combination product is indicated for otic or ophthalmic use only. Not for injection. Neomycin carries a risk of ototoxicity and nephrotoxicity if absorbed systemically; avoid in patients with perforated tympanic membrane. Bacitracin zinc and polymyxin B cover gram-positive and gram-negative organisms, respectively. Hydrocortisone reduces inflammation. Use caution in patients with known hypersensitivity to any component; cross-reactivity among aminoglycosides is possible. For otic use, keep the ear canal dry during treatment. Do not use for more than 10 days without re-evaluation.
No interactions on record
No interactions on record
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE and NEOMYCIN & POLYMYXIN B SULFATES & BACITRACIN ZINC & HYDROCORTISONE are distinct pharmacological agents. NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE belongs to the Aminoglycoside Antibiotic class and is primarily used for Otic infections: treatment of superficial bacterial infections of the external auditory canal (acute otitis externa)Otic infections: treatment of infections of mastoidectomy and fenestration cavitiesOphthalmic infections: treatment of corticosteroid-responsive inflammatory ocular conditions with concurrent bacterial infection (off-label). NEOMYCIN & POLYMYXIN B SULFATES & BACITRACIN ZINC & HYDROCORTISONE belongs to the Aminoglycoside Antibiotic class and is primarily used for Treatment of corticosteroid-responsive dermatoses with secondary bacterial infection. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE carries a safety status of Category A/B, whereas NEOMYCIN & POLYMYXIN B SULFATES & BACITRACIN ZINC & HYDROCORTISONE safety is classified as Category A/B. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Neomycin: not significantly metabolized, excreted unchanged by kidneys. Polymyxin B: not significantly metabolized, excreted primarily by renal filtration. Hydrocortisone: metabolized in the liver via reduction and conjugation, primarily to tetrahydrocortisone and glucuronide conjugates.
Neomycin is minimally metabolized; polymyxin B is not significantly metabolized; bacitracin is not metabolized; hydrocortisone is hepatically metabolized primarily by CYP3A4.
Neomycin: >90% unchanged in feces after oral administration; negligible renal excretion. Polymyxin B: 60% renal excretion of unchanged drug; remainder nonrenal. Hydrocortisone: primarily hepatic metabolism, <5% renal excretion unchanged.
Neomycin: >90% renal (unchanged) after parenteral; polymyxin B: ~60% renal (unchanged) over 72h; bacitracin: >90% renal (unchanged) after IM; hydrocortisone: hepatic metabolism, metabolites renally eliminated (<1% unchanged). Topical: negligible systemic absorption across intact skin (except bacitracin may be minimally absorbed).
Neomycin: negligible (0-10% bound). Polymyxin B: ~80-90% bound to albumin and other proteins. Hydrocortisone: ~90% bound to corticosteroid-binding globulin (CBG) and albumin.
Neomycin: <30% bound; polymyxin B: ~50-60% bound; bacitracin: ~70-80% bound; hydrocortisone: ~90% bound to corticosteroid-binding globulin (CBG) and albumin.
Neomycin: 0.25 L/kg (primarily extracellular fluid). Polymyxin B: 0.25-0.5 L/kg (distributes to tissues, limited CNS penetration). Hydrocortisone: 0.4 L/kg (distributes widely, including breast milk and placenta).
Neomycin: 0.2-0.4 L/kg (limited to extracellular fluid); polymyxin B: 0.6-1.0 L/kg; bacitracin: ~0.3 L/kg (IM); hydrocortisone: ~0.4 L/kg. Topical: negligible systemic Vd.
Oral neomycin: <3% (poorly absorbed). Oral polymyxin B: negligible (<0.5%). Topical/ophthalmic/otic administration: minimal systemic absorption (<1% for polymyxin B and neomycin; hydrocortisone may be absorbed to a small degree but typically <1%).
Topical ophthalmic/otic: negligible systemic bioavailability (<0.1% for neomycin, polymyxin B, bacitracin; hydrocortisone minimally absorbed); IM bacitracin: ~100% (not given IV); oral (neomycin): <3% (used for gut decontamination).
No systemic absorption expected with otic use; no dose adjustment required.
No adjustment necessary for ophthalmic/otic/topical use due to minimal systemic absorption.
Instill 3 drops into the affected ear(s) 3 times daily for children; dose similar to adult due to lack of systemic absorption.
Apply to affected area 3-4 times daily. Safe for children >2 years; use with caution in infants due to potential for systemic absorption.
No specific adjustment; use same as adult dosing. Monitor for local irritation or hypersensitivity.
No specific adjustment required. Use caution with prolonged use due to potential for increased systemic absorption with thinner skin.
None
No known food interactions. Avoid alcohol as it may worsen dizziness or side effects.
No significant food interactions. Avoid alcohol with systemic corticosteroids, but topical/otic use has minimal absorption. No specific dietary restrictions.
Pregnancy Category C. Neomycin and polymyxin B sulfate are poorly absorbed systemically, but bacitracin zinc is nephrotoxic if absorbed. Hydrocortisone is a corticosteroid; systemic absorption may increase risk of orofacial clefts (first trimester) and adrenal suppression (third trimester). Limited human data; risk cannot be excluded. Use only if potential benefit justifies risk.
Neomycin and polymyxin B sulfates are minimally absorbed topically, and systemic levels are negligible; thus, transfer into breast milk is unlikely. Hydrocortisone is excreted in breast milk in small amounts, but topical application to limited areas is not expected to cause adverse effects in the infant. No M/P ratio is available. Use with caution, avoiding application to breast area.
Minimal systemic absorption of topical components; unlikely to appear in breast milk. M/P ratio not available. Corticosteroids are excreted in milk but at low doses. Caution with prolonged use on large areas. Generally considered compatible with breastfeeding.
No dosage adjustment required for topical use as systemic absorption is negligible. Avoid prolonged use on large areas or under occlusive dressings to minimize potential systemic effects.
No pharmacokinetic changes known for topical application. Use lowest effective dose, shortest duration. Avoid prolonged use on large areas or under occlusion to minimize systemic absorption.
Use exactly as prescribed; do not stop early even if symptoms improve.,Shake the bottle well before each use.,Lie down with the affected ear upward for at least 5 minutes after applying drops.,Do not touch the dropper tip to the ear or any surface to avoid contamination.,Contact your doctor if you experience ringing in the ears, hearing loss, or dizziness.,Do not use if you have a perforated eardrum or if ear discharge is present without consulting a doctor.,Avoid swimming or getting water in the ear during treatment.
Use this medication exactly as prescribed; do not use for longer than directed.,For ear drops, lie on your side with the affected ear up, instill the drops, and remain for 5 minutes to allow penetration.,For eye ointment, apply a thin strip to the affected eye; avoid touching the tip to any surface.,Do not use if you have a hole in your eardrum (perforated tympanic membrane) or a viral or fungal eye infection.,Notify your doctor if you experience new or worsening hearing loss, ringing in the ears, dizziness, or kidney problems.,Discontinue use and seek medical attention if you develop a rash, swelling, or difficulty breathing.,Keep the medication tightly closed and store at room temperature away from light.